Further Information
CDH2, CDw325, CDHN, Cadherin-2, CD325, CD325 antigen, N Cadherin, N-cadherin, NCAD, Neural cadherin, N-cadherin 1, Neural-cadherin
Flow Cytometry: 0.5-1ug/10^6 cells in 0.1ml
IF: 1-2 ug/ml
WB: 0.5-1 ug/ml
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the N-Cadherin antibody to be titered up or down for optimal performance.
Recognizes a protein of ~140kDa, identified as N-Cadherin (NCAD), also known as CDH2 and CD325. NCAD is a member of the Cadherin superfamily, and consists of five extracellular repeats, a transmembrane domain and a cytoplasmic domain. NCAD/CD325 deficient mice die at day 10 of gestation and embryos display major heart defects and malformed neural tubes and somites. Consistent with this, the protein has been implicated in several aspects of cardiac development including the precardiac mesoderm, establishment of left-right symmetry and cardiac looping morphogenesis. Furthermore, it is normally involved in inducing cell cycle arrest and its expression is frequently deregulated in cancer cells. Studies have linked N-cadherin to cancer metastasis by showing the aggressive tumor cells had preferentially turned on N-cadherin as opposed to E- or P-cadherin.
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
0.2 mg/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
A human partial recombinant protein corresponding to the CDH2/NCAD cytoplasmic domain was used as the immunogen for this N-Cadherin antibody.
1000
cadherin 2, type 1, N-cadherin (neuronal)
CDH2
Homo sapiens
Liquid
Protein G affinity chromatography
Cancer, Signal Transduction, Stem Cell
P19022
Optimal dilutions for each application to be determined by the researcher